RIO DE JANEIRO, BRAZIL - Although it has not yet been cleared by regulators, Merck's molnupiravir pill has been celebrated as a potential breakthrough, because it could be relatively cheap and easy to manufacture, does not require infusion, and has been shown to reduce the risk of hospitalization in a trial.
However, it may need to be combined with other drugs to prevent resistance, Wellcome Foundation director Jeremy Farrar said.
Resistance occurs when viruses and bacteria evolve to halt or defeat the drugs' attack mechanism. It is an ongoing concern with antivirals and antibiotics and has been seen in treatments . . .